$BCAB
BioAtla, Inc.

2021 Q2 Form 10-Q Financial Statement

#000095017021000192 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $250.0K $0.00 $90.00K
YoY Change 31.58% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.86M $8.370M -$460.0K
YoY Change 787.52% -1919.57%
% of Gross Profit
Research & Development $14.85M $10.42M $1.661M
YoY Change 408.04% 527.51%
% of Gross Profit
Depreciation & Amortization $326.0K $309.0K $216.0K
YoY Change -24.36% 43.06%
% of Gross Profit
Operating Expenses $30.71M $18.80M $1.198M
YoY Change 552.02% 1469.03%
Operating Profit -$30.46M -$18.80M -$1.109M
YoY Change 573.89% 1594.95%
Interest Expense $1.000K $2.000K $547.0K
YoY Change -99.87% -99.63%
% of Operating Profit
Other Income/Expense, Net $79.00K $96.00K -$495.0K
YoY Change -104.64% -119.39%
Pretax Income -$30.38M -$18.70M -$1.600M
YoY Change 388.28% 1068.75%
Income Tax
% Of Pretax Income
Net Earnings -$30.38M -$18.70M -$1.604M
YoY Change 388.28% 1065.9%
Net Earnings / Revenue -12152.4% -1782.22%
Basic Earnings Per Share
Diluted Earnings Per Share -$902.1K -$555.6K -$0.05
COMMON SHARES
Basic Shares Outstanding 32.17M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $207.6M $221.2M
YoY Change
Cash & Equivalents $207.6M $221.2M $370.0K
Short-Term Investments
Other Short-Term Assets $4.722M $3.400M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $212.3M $224.6M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $4.223M $4.351M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $154.0K $154.0K
YoY Change
Total Long-Term Assets $4.377M $4.505M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $212.3M $224.6M
Total Long-Term Assets $4.377M $4.505M
Total Assets $216.7M $229.1M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.283M $2.505M
YoY Change
Accrued Expenses $2.240M $800.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.16M $30.53M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $682.0K $700.0K
YoY Change
Other Long-Term Liabilities $1.847M $2.000M
YoY Change
Total Long-Term Liabilities $2.529M $2.700M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $36.16M $30.53M
Total Long-Term Liabilities $2.529M $2.700M
Total Liabilities $38.69M $33.17M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$140.0M -$109.6M
YoY Change
Common Stock $3.000K $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.0M $195.9M -$57.62M
YoY Change
Total Liabilities & Shareholders Equity $216.7M $229.1M
YoY Change

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$30.38M -$18.70M -$1.604M
YoY Change 388.28% 1065.9%
Depreciation, Depletion And Amortization $326.0K $309.0K $216.0K
YoY Change -24.36% 43.06%
Cash From Operating Activities -$13.55M -$14.99M -$3.814M
YoY Change 97.33% 293.13%
INVESTING ACTIVITIES
Capital Expenditures -$236.0K -$500.0K $20.00K
YoY Change 174.42% -2600.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$236.0K -$501.0K -$20.00K
YoY Change 174.42% 2405.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 189.0K -1.911M 500.0K
YoY Change -94.49% -482.2%
NET CHANGE
Cash From Operating Activities -13.55M -14.99M -3.814M
Cash From Investing Activities -236.0K -501.0K -20.00K
Cash From Financing Activities 189.0K -1.911M 500.0K
Net Change In Cash -13.60M -17.41M -3.334M
YoY Change 286.25% 422.08%
FREE CASH FLOW
Cash From Operating Activities -$13.55M -$14.99M -$3.814M
Capital Expenditures -$236.0K -$500.0K $20.00K
Free Cash Flow -$13.31M -$14.49M -$3.834M
YoY Change 96.36% 278.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-07-13
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 bcab Collaboration Agreement Start Date
CollaborationAgreementStartDate
2019-12
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001826892
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-39787
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
BIOATLA, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1922320
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11085 Torreyana Road
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
558-0708
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
BCAB
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32171560
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221199000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
238605000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305531000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300888000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
195916000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12068000
CY2021Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
393000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
387000
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19806000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19806000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30530000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90917000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3383000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2076000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
224582000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
240681000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4351000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4102000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154000
CY2021Q1 us-gaap Assets
Assets
229087000
CY2020Q4 us-gaap Assets
Assets
244937000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10331000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32261000
CY2021Q1 bcab Long Term Accrued Interest
LongTermAccruedInterest
6000
CY2020Q4 bcab Long Term Accrued Interest
LongTermAccruedInterest
5000
CY2021Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1953000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2015000
CY2021Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
682000
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
682000
CY2021Q1 us-gaap Liabilities
Liabilities
33171000
CY2020Q4 us-gaap Liabilities
Liabilities
34963000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32171560
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32171560
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32171560
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32171560
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109618000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
209974000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229087000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
244937000
CY2021Q1 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0
CY2020Q1 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
89000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10423000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1661000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8374000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
463000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
18797000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
1198000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18797000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1109000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
98000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2020Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
59000
CY2021Q1 us-gaap Interest Expense
InterestExpense
2000
CY2020Q1 us-gaap Interest Expense
InterestExpense
547000
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
47000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-495000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18701000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1604000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33663619
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
209974000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4643000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18701000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
195916000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18701000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1604000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
309000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
216000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
47000
CY2021Q1 bcab Change In Fair Value And Pushdown Of Profits Interest Liability
ChangeInFairValueAndPushdownOfProfitsInterestLiability
0
CY2020Q1 bcab Change In Fair Value And Pushdown Of Profits Interest Liability
ChangeInFairValueAndPushdownOfProfitsInterestLiability
5703000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4643000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2021Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
0
CY2020Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
167000
CY2021Q1 bcab Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
56000
CY2020Q1 bcab Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
27000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1307000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
414000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
117000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2480000
CY2021Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
1000
CY2020Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
379000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-89000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14994000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3814000
CY2021Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
501000
CY2020Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
20000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-501000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2020Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
500000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
-1911000
CY2020Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1911000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
500000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17406000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3334000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
238605000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3704000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221199000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
370000
CY2021Q1 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
74000
CY2020Q1 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
155000
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 bcab Company Formation Date
CompanyFormationDate
2007-03
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6220050
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109600000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="padding-top:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="padding-top:6.0pt;text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to revenue recognition, accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="padding-top:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Risk</span></p><p style="padding-top:6.0pt;text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3280329
CY2021Q1 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
1025000
CY2020Q4 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
2004000
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2231000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
0
CY2021Q1 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
127000
CY2020Q4 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
72000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3383000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2076000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7730000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7172000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3379000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3070000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4351000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4102000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2505000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2456000
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
833000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2804000
CY2021Q1 bcab Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5921000
CY2020Q4 bcab Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4852000
CY2021Q1 bcab Accrued Equity Issuance Costs Current
AccruedEquityIssuanceCostsCurrent
0
CY2020Q4 bcab Accrued Equity Issuance Costs Current
AccruedEquityIssuanceCostsCurrent
1143000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1072000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
813000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10331000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12068000
CY2021Q1 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2020Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2021Q1 us-gaap Debt Conversion Description
DebtConversionDescription
The Company issued convertible promissory notes between December 2015 and May 2020 totaling $21.8 million, of which $2.0 million was with related parties. The convertible promissory notes accrued interest at 8% per annum with maturity dates of five years after issuance. The convertible promissory notes were settled in connection with the Company’s Series D financing in July 2020.
CY2021Q1 bcab Debt Instrument Outstanding Principal Amount
DebtInstrumentOutstandingPrincipalAmount
700000
CY2017Q2 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
The lease commenced in January 2018, the period the Company gained access to the leased space and began recognizing rent expense. The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years.
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2020Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1057000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1555000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1636000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1685000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
845000
CY2021Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6778000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-56011000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1604000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-57615000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4643000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.00
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y11M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y7M6D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y7M6D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7640
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.52
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y9M7D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.15
CY2021Q1 bcab Outstanding And Exercisable Common Stock Warrants
OutstandingAndExercisableCommonStockWarrants
717674
CY2021Q1 bcab Warrants For The Purchase Of Common Stock
WarrantsForThePurchaseOfCommonStock
717674
CY2020 bcab Warrants For The Purchase Of Common Stock
WarrantsForThePurchaseOfCommonStock
717674
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7778207
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6122181
CY2021Q1 bcab Upfront Non Refundable Payment
UpfrontNonRefundablePayment
20000000.0
CY2021Q1 bcab Agreement Transaction Price
AgreementTransactionPrice
25000000.0
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19800000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19800000
CY2021Q1 bcab Debt Instrument Settled Date
DebtInstrumentSettledDate
2020-07
CY2021Q1 us-gaap Related Party Transaction Terms And Manner Of Settlement
RelatedPartyTransactionTermsAndMannerOfSettlement
On March 18, 2021, the Company and Carolyn Anderson Short, its co-founder and Chief of Intellectual Property & Strategy, mutually agreed that Ms. Short would depart the Company on May 31, 2021 following an agreed upon transition period. The Transition Agreement provides for the following severance benefits in exchange for a release of claims by Ms. Short: (i) a lump sum payment equal to eighteen (18) months of Ms. Short’s current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the separation date, and (iii) accelerated full vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units. The modification of these equity awards resulted in an incremental fair value of $7.0 million which will be recognized on a straight-line basis over the transition service period. For the three months ended March 31, 2021, the Company recognized $0.2 million related to the lump sum salary payment and target bonus, and a $1.0 million non-cash charge related to the modified equity awards.
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0

Files In Submission

Name View Source Status
0000950170-21-000192-index-headers.html Edgar Link pending
0000950170-21-000192-index.html Edgar Link pending
0000950170-21-000192.txt Edgar Link pending
0000950170-21-000192-xbrl.zip Edgar Link pending
bcab-20210331-ex10_1.htm Edgar Link pending
bcab-20210331-ex31_1.htm Edgar Link pending
bcab-20210331-ex31_2.htm Edgar Link pending
bcab-20210331-ex32_1.htm Edgar Link pending
bcab-20210331.htm Edgar Link pending
bcab-20210331.xsd Edgar Link pending
bcab-20210331_cal.xml Edgar Link unprocessable
bcab-20210331_def.xml Edgar Link unprocessable
bcab-20210331_htm.xml Edgar Link completed
bcab-20210331_lab.xml Edgar Link unprocessable
bcab-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending